Table 2 Characteristics of patients sub-categorized by groups
No COVID-19 | COVID-19 and no vaccination | COVID-19 and vaccination | p value | ||||
|---|---|---|---|---|---|---|---|
Age (years) | 54.8 | ± 15.0 | 56.4 | ± 14.9 | 56.6 | ± 15.0 | 0.454 |
Sex-Male (n,%) | 87 (42%) | 89 (48.1%) | 47(31.8%) | 0.010 | |||
Neurological deficits (n, %) | 94 (45.4%) | 121(65.4%) | 86(58.1%) | < 0.001 | |||
Malignance (n, %) | 83(40.1%) | 64(34.6%) | 49(33.1%) | 0.337 | |||
Total TV (cc) (n = 538) | 4.3 | ± 5.7 | 40.6 | ± 5.9 | 3.7 | ± 4.6 | 0.108 |
Peripheral dose (GY) | 16.5 | ± 3.9 | 16.1 | ± 5.9 | 15.8 | ± 5.7 | 0.003 |
Number of lesions | 1.9 | ± 1.9 | 1.5 | ± 1.3 | 1.4 | ± 1.1 | 0.011 |
KPS | 83.1 | ± 8.5 | 83.9 | ± 7.3 | 84.7 | ± 8.4 | 0.208 |
ECOG | 1.1 | ± 1.1 | 0.7 | ± 0.7 | 0.7 | ± 0.7 | < 0.001 |
Charlson comorbidity index | 3.9 | ± 3.3 | 4.6 | ± 3.2 | 3.1 | ± 3.1 | < 0.001 |
Time from diagnosis to GK treatment (days) | 45.0 | ± 28.0 | 54.5 | ± 27.6 | 29.6 | ± 10.9 | < 0.001 |
Time from diagnosis to GK consultation (days) | 17.1 | ± 22.4 | 36.8 | ± 25.5 | 12.2 | ± 7.1 | < 0.001 |
Duration of GK treatment (hours) | 4.8 | ± 1.4 | 5.1 | ± 1.4 | 5.2 | ± 1.4 | 0.007 |
OPD frequency (time/year) | 13.7 | ± 7.6 | 6.9 | ± 6.0 | 10.0 | ± 6.3 | < 0.001 |
MRI frequency (time/year) | 2.6 | ± 1.1 | 1.0 | ± 1.0 | 2.3 | ± 1.0 | < 0.001 |